Abstract

In clinical trials conducted over several data collection centers, the most common statistically defensible analytic method, a stratified Cox model analysis, suffers from two important defects. First, identification of units that are outlying with respect to the baseline hazard is awkward since this hazard is implicit (rather than explicit) in the Cox partial likelihood. Second (and more seriously), identification of modest treatment effects is often difficult since the model fails to acknowledge any similarity across the strata. We consider a number of hierarchical modeling approaches that preserve the integrity of the stratified design while offering a middle ground between traditional stratified and unstratified analyses. We investigate both fully parametric (Weibull) and semiparametric models, the latter based not on the Cox model but on an extension of an idea by Gelfand and Mallick (1995, Biometrics 51, 843-852), which models the integrated baseline hazard as a mixture of monotone functions. We illustrate the methods using data from a recent multicenter AIDS clinical trial, comparing their ease of use, interpretation, and degree of robustness with respect to estimates of both the unit-specific baseline hazards and the treatment effect.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.